View Future GrowthThis company listing is no longer activeThis company may still be operating, however this listing is no longer active. Find out why through their latest events.See Latest EventsPharmasimple 과거 순이익 실적과거 기준 점검 0/6지난 몇 년간 Pharmasimple 의 실적에 대한 데이터가 부족합니다.핵심 정보n/a순이익 성장률n/a주당순이익(EPS) 성장률Specialty Retail 산업 성장률14.47%매출 성장률n/a자기자본이익률n/a순이익률n/a최근 순이익 업데이트30 Jun 2021최근 과거 실적 업데이트Reported Earnings • Apr 15Full year 2021 earnings: Revenues in line with analyst expectationsFull year 2021 results: Revenue: €30.0m (down 35% from FY 2020). Net loss: €9.10m (loss widened 499% from FY 2020). Revenue was in line with analyst estimates.Reported Earnings • Apr 16Full year 2020 earnings releasedThe company reported a solid full year result with reduced losses, improved revenues and improved control over expenses. Full year 2020 results: Revenue: €45.2m (up 61% from FY 2019). Net loss: €1.50m (loss narrowed 46% from FY 2019).모든 업데이트 보기Recent updatesBoard Change • Jun 28No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 4 non-independent directors. Director Didier Petre was the last director to join the board, commencing their role in 2021. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.Board Change • Nov 16No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 2 experienced directors. 1 highly experienced director. No independent directors (3 non-independent directors). Director Alexandre Plissart was the last director to join the board, commencing their role in 2017. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.Board Change • Apr 27No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 2 experienced directors. 1 highly experienced director. No independent directors (3 non-independent directors). Director Alexandre Plissart was the last director to join the board, commencing their role in 2017. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.Reported Earnings • Apr 15Full year 2021 earnings: Revenues in line with analyst expectationsFull year 2021 results: Revenue: €30.0m (down 35% from FY 2020). Net loss: €9.10m (loss widened 499% from FY 2020). Revenue was in line with analyst estimates.공시 • Sep 01Pharmasimple SA announced that it expects to receive €10 million in funding from Alpha Blue Ocean IncPharmasimple SA announced a private placement of bonds convertible into shares with a maximum amount of €10 million in a round of funding on August 31, 2021. The transaction will include participation from Alpha Blue Ocean. The convertible bonds with a nominal value of 5,000 euros will be subscribed in increments of 0.5 million euros, which means that a maximum of 20 tranches, representing a total of 2,000 convertible bonds, may be subscribed until August 27, 2026.분석 기사 • Jul 31One Analyst Just Shaved Their Pharmasimple SA (EPA:ALPHS) Forecasts DramaticallyThe analyst covering Pharmasimple SA ( EPA:ALPHS ) delivered a dose of negativity to shareholders today, by making a...Major Estimate Revision • Jul 23Consensus forecasts updatedThe consensus outlook for 2021 has been updated. 2021 expected loss increased from -€0.43 to -€0.60 per share. Revenue forecast of €36.7m unchanged since last update. Online Retail industry in France expected to see average net income growth of 5.1% next year. Consensus price target down from €11.00 to €9.80. Share price was steady at €6.40 over the past week.Breakeven Date Change • May 26No longer forecast to breakevenThe analyst covering Pharmasimple no longer expects the company to break even during the foreseeable future. The company was expected to make a profit of €1.10m in 2021. New forecast suggests the company will make a loss of €500.0k in 2022.Price Target Changed • May 26Price target decreased to €11.00Down from €14.30, the current price target is provided by 1 analyst. New target price is 44% above last closing price of €7.62. Stock is down 39% over the past year.Reported Earnings • Apr 16Full year 2020 earnings releasedThe company reported a solid full year result with reduced losses, improved revenues and improved control over expenses. Full year 2020 results: Revenue: €45.2m (up 61% from FY 2019). Net loss: €1.50m (loss narrowed 46% from FY 2019).분석 기사 • Apr 12Analysts Expect Pharmasimple SA (EPA:ALPHS) To Breakeven SoonPharmasimple SA ( EPA:ALPHS ) is possibly approaching a major achievement in its business, so we would like to shine...Is New 90 Day High Low • Dec 28New 90-day high: €10.35The company is up 7.0% from its price of €9.70 on 29 September 2020. The French market is up 14% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Online Retail industry, which is up 52% over the same period.분석 기사 • Dec 27Analysts Expect Pharmasimple SA (EPA:ALPHS) To Breakeven SoonPharmasimple SA ( EPA:ALPHS ) is possibly approaching a major achievement in its business, so we would like to shine...Is New 90 Day High Low • Nov 17New 90-day low: €8.76The company is down 9.0% from its price of €9.60 on 19 August 2020. The French market is up 12% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Online Retail industry, which is up 27% over the same period.Is New 90 Day High Low • Oct 26New 90-day low: €8.86The company is down 9.0% from its price of €9.78 on 28 July 2020. The French market is up 1.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Online Retail industry, which is up 20% over the same period.매출 및 비용 세부 내역Pharmasimple가 돈을 벌고 사용하는 방법. 최근 발표된 LTM 실적 기준.순이익 및 매출 추이ENXTPA:ALPHS 매출, 비용 및 순이익 (EUR Millions)날짜매출순이익일반관리비연구개발비30 Jun 2132-51031 Mar 2139-31031 Dec 2046-20030 Sep 2045-20030 Jun 2044-10031 Mar 2036-20031 Dec 1928-30030 Sep 1926-30030 Jun 1923-20031 Mar 1920-20031 Dec 1817-20030 Sep 1818-20030 Jun 1818-20031 Mar 1819-20031 Dec 1719-10030 Sep 1717-10030 Jun 1715-10031 Mar 1713-10031 Dec 1611-10031 Dec 15700031 Dec 14500031 Dec 134000양질의 수익: ALPHS가 고품질 수익을 갖고 있는지 판단하기에는 데이터가 부족합니다.이익 마진 증가: 지난 1년 동안 ALPHS의 이익률이 개선되었는지 판단하기에 데이터가 부족합니다.잉여현금흐름 대비 순이익 분석과거 순이익 성장 분석수익추이: 지난 5년 동안 ALPHS의 연간 수익 성장률이 양(+)이었는지 판단하기에 데이터가 부족합니다.성장 가속화: ALPHS의 지난해 수익 성장률을 5년 평균과 비교하기에 데이터가 부족합니다.수익 대 산업: ALPHS의 지난 해 수익 증가율이 Specialty Retail 업계 평균을 상회했는지 판단하기에 데이터가 부족합니다.자기자본이익률높은 ROE: ALPHS는 현재 수익성이 없으므로 자본 수익률이 음수(0%)입니다.총자산이익률투하자본수익률우수한 과거 실적 기업을 찾아보세요7D1Y7D1Y7D1YRetail 산업에서 과거 실적이 우수한 기업.View Financial Health기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2024/02/09 16:12종가2024/02/09 00:00수익2021/06/30연간 수익2020/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Pharmasimple SA는 1명의 분석가가 다루고 있습니다. 이 중 명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Florent Thy-TineTPICAP Midcap
Reported Earnings • Apr 15Full year 2021 earnings: Revenues in line with analyst expectationsFull year 2021 results: Revenue: €30.0m (down 35% from FY 2020). Net loss: €9.10m (loss widened 499% from FY 2020). Revenue was in line with analyst estimates.
Reported Earnings • Apr 16Full year 2020 earnings releasedThe company reported a solid full year result with reduced losses, improved revenues and improved control over expenses. Full year 2020 results: Revenue: €45.2m (up 61% from FY 2019). Net loss: €1.50m (loss narrowed 46% from FY 2019).
Board Change • Jun 28No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 4 non-independent directors. Director Didier Petre was the last director to join the board, commencing their role in 2021. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.
Board Change • Nov 16No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 2 experienced directors. 1 highly experienced director. No independent directors (3 non-independent directors). Director Alexandre Plissart was the last director to join the board, commencing their role in 2017. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.
Board Change • Apr 27No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 2 experienced directors. 1 highly experienced director. No independent directors (3 non-independent directors). Director Alexandre Plissart was the last director to join the board, commencing their role in 2017. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.
Reported Earnings • Apr 15Full year 2021 earnings: Revenues in line with analyst expectationsFull year 2021 results: Revenue: €30.0m (down 35% from FY 2020). Net loss: €9.10m (loss widened 499% from FY 2020). Revenue was in line with analyst estimates.
공시 • Sep 01Pharmasimple SA announced that it expects to receive €10 million in funding from Alpha Blue Ocean IncPharmasimple SA announced a private placement of bonds convertible into shares with a maximum amount of €10 million in a round of funding on August 31, 2021. The transaction will include participation from Alpha Blue Ocean. The convertible bonds with a nominal value of 5,000 euros will be subscribed in increments of 0.5 million euros, which means that a maximum of 20 tranches, representing a total of 2,000 convertible bonds, may be subscribed until August 27, 2026.
분석 기사 • Jul 31One Analyst Just Shaved Their Pharmasimple SA (EPA:ALPHS) Forecasts DramaticallyThe analyst covering Pharmasimple SA ( EPA:ALPHS ) delivered a dose of negativity to shareholders today, by making a...
Major Estimate Revision • Jul 23Consensus forecasts updatedThe consensus outlook for 2021 has been updated. 2021 expected loss increased from -€0.43 to -€0.60 per share. Revenue forecast of €36.7m unchanged since last update. Online Retail industry in France expected to see average net income growth of 5.1% next year. Consensus price target down from €11.00 to €9.80. Share price was steady at €6.40 over the past week.
Breakeven Date Change • May 26No longer forecast to breakevenThe analyst covering Pharmasimple no longer expects the company to break even during the foreseeable future. The company was expected to make a profit of €1.10m in 2021. New forecast suggests the company will make a loss of €500.0k in 2022.
Price Target Changed • May 26Price target decreased to €11.00Down from €14.30, the current price target is provided by 1 analyst. New target price is 44% above last closing price of €7.62. Stock is down 39% over the past year.
Reported Earnings • Apr 16Full year 2020 earnings releasedThe company reported a solid full year result with reduced losses, improved revenues and improved control over expenses. Full year 2020 results: Revenue: €45.2m (up 61% from FY 2019). Net loss: €1.50m (loss narrowed 46% from FY 2019).
분석 기사 • Apr 12Analysts Expect Pharmasimple SA (EPA:ALPHS) To Breakeven SoonPharmasimple SA ( EPA:ALPHS ) is possibly approaching a major achievement in its business, so we would like to shine...
Is New 90 Day High Low • Dec 28New 90-day high: €10.35The company is up 7.0% from its price of €9.70 on 29 September 2020. The French market is up 14% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Online Retail industry, which is up 52% over the same period.
분석 기사 • Dec 27Analysts Expect Pharmasimple SA (EPA:ALPHS) To Breakeven SoonPharmasimple SA ( EPA:ALPHS ) is possibly approaching a major achievement in its business, so we would like to shine...
Is New 90 Day High Low • Nov 17New 90-day low: €8.76The company is down 9.0% from its price of €9.60 on 19 August 2020. The French market is up 12% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Online Retail industry, which is up 27% over the same period.
Is New 90 Day High Low • Oct 26New 90-day low: €8.86The company is down 9.0% from its price of €9.78 on 28 July 2020. The French market is up 1.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Online Retail industry, which is up 20% over the same period.